FLT1 and breast cancer: Another potent VEGFR1 inhibitor is the mAb IMC-18F1 (icrucumab, Eli Lilly and Company), which in preclinical models of breast cancer inhibits tumor xenograft growth and synergizes with different chemotherapeutics, including cyclophosphamide or doxorubicin [16, 24].